M0237 Insurance Policy Changes

HCPCS M0237 is officially defined as "Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose." HCPCS M0237 is referenced in 2 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS M0237 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.